Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Lenbelintide

Lenbelintide

Amylin · s.c. · AstraZeneca

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
AZD6234, AstraZeneca
Mechanism
Amylin
Route
s.c.
Company
AstraZeneca
Highest development stage
phase 3
Status (as of data cut)
Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks) verify
Next milestone
Phase 3 readout

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 recruiting: adjunct to incretin-based therapy, 68 weeksAZD6234 phase 3
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
SELENE-Asia
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
ObesityPhase 3not yet recruiting2027-01 → 2028-09330not yet recruitingNCT07922330
SELENE 3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
ObesityPhase 3recruiting2026-08 → 2028-08500recruitingNCT07776509
SELENE 2
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
ObesityPhase 3recruiting2026-08 → 2028-081500recruitingNCT07784270
SELENE 1
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
ObesityPhase 3recruiting2026-08 → 2028-082500recruitingNCT07784725

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: Lenbelintide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/lenbelintide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.